(Nasdaq: MODD)
****Sponsored by LFG Equities Corp and Disseminated on behalf of Modular Medical
MODD’s Pivot™️ is a removable two-part design tubeless patch pump with a 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required - all while maintaining clinical accuracy and connectivity
The "Almost-Pumpers" Finally Have a Device Built for Them — And the Company Behind It Just Cleared Its Biggest Hurdle
FDA Cleared, Launch Imminent: Why This Under-the-Radar Diabetes Device Company Could Be the Most Important Medical Device Story of Fall 2026
CHECK OUT THE INVESTOR PRESENTATION
Hello Everyone,
There's a quiet revolution unfolding in the world of diabetes care, and it's not coming from a biotech giant with a billion-dollar R&D budget. It's coming from a lean, focused medical device company headquartered in San Diego, California, that spent years engineering a single answer to one of healthcare's most persistent questions: why do roughly 70% of insulin-dependent adults still rely on daily injections when pump technology has existed for decades?
The answer, as Modular Medical, Inc. (Nasdaq: MODD) identified early on, came down to what CEO Jeb Besser calls the "three Cs" — complexity, cumbersomeness, and cost. Traditional insulin pumps, while effective, have long carried a barrier to entry that kept millions of potential users on the sidelines. These are the "almost-pumpers," adults living with Type 1 or Type 2 diabetes who want better outcomes but have been priced out, intimidated out, or simply turned off by what was available. That calculation may be changing.
The company just dropped some substantial news this week that is still in play: The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market with Commercial expansion activities expected to begin in Q4 2026.
Before diving into the full story, here is why MODD is drawing attention right now. One of the most significant de-risking events in any medical device company's lifecycle arrived on April 9th, 2026 for MODD, when the FDA granted 510(k) clearance for the Pivot™️ tubeless insulin patch pump. The Pivot is the first two-part tubeless patch pump featuring a removable 3 mL reservoir, disposable battery, smartphone connectivity for bolus and monitoring, and true electronic accuracy without tubes or constant wear, giving MODD a potential first-mover position in a segment that has never had a device like this. The "almost-pumper" segment — roughly 70% of insulin-dependent adults still on daily injections — represents an estimated $3 billion addressable market that MODD is now commercially cleared to pursue. With commercial launch targeted for fall 2026 and initial patients expected soon, MODD is entering its most operationally consequential period since the company's founding. With Yahoo Finance reporting a float of approximately 2.22 million shares, there is strong potential for significant volatility on a daily basis. And the May 2025 addition of Jeff Goldberg — a veteran of Alfred E. Mann's medical device incubator and current Chairman of Lannett Company — brought meaningful experience in drug-device combinations and affordable insulin delivery directly to the MODD board.
On April 9th, 2026, Modular Medical received U.S. Food and Drug Administration 510(k) clearance for its next-generation Pivot™ tubeless insulin patch pump, a device the company describes as the first two-part removable tubeless patch pump designed specifically for this overlooked patient population. Within weeks, the company launched PivotPump.com, a patient-facing digital hub designed to guide potential users through their options. Commercial launch is targeted for the fall of 2026. For market watchers who track medical device names in pre-commercial or early-commercial phases, this is precisely the kind of inflection point that tends to draw attention before the broader conversation catches up. MODD has cleared its most significant regulatory hurdle. The next chapter is execution.
The Pivot™ is not simply an incremental improvement on existing patch pumps. It is structured as a two-part system: a reusable pump body paired with a disposable 3 mL reservoir and battery. This design allows the wearer to remove the pump for showering, sports, or discretion — a feature no other tubeless patch pump currently on the market offers in this configuration. It also delivers electronic dosing accuracy without tubing, constant wear requirements, or a separate handheld controller. Smartphone connectivity for bolus delivery and real-time monitoring is built in. Software enhancements already in the pipeline include variable bolus options, improved alarm systems, and compatibility with automated closed-loop insulin delivery systems, a feature set that positions Pivot as a potential gateway device into the growing automated insulin delivery ecosystem.
Modular Medical has consistently framed its commercial target as the "almost-pumper" segment, a term that captures approximately 70% of insulin-dependent adults who remain on multiple daily injections despite qualifying as candidates for pump therapy. The company estimates the addressable market at approximately $3 billion. The case for this segment is built on clinical logic as much as commercial math. Research consistently shows that pump therapy can improve long-term glycemic outcomes and potentially reduce downstream healthcare costs, yet barriers to adoption have kept the majority of eligible patients on injections. A device that directly targets affordability, simplicity, and wearability addresses those specific friction points without asking patients to compromise on clinical outcomes.
Modular Medical's manufacturing platform was deliberately engineered from the ground up for high-volume, low-cost production — a design decision that is now paying dividends. The company completed its MODD1 cartridge production run at over 6,000 units prior to transitioning the line to Pivot production. Validation production lots for both the Pivot cartridge and infusion set were reported underway by early 2026. Initial production capacity targets approximately 6,000 users, with the platform designed for rapid scaling as commercial demand materializes.
When FDA clearance arrived, CEO Jeb Besser didn't reach for corporate boilerplate. His public statement was direct, and it told a specific story about years of focused engineering work reaching its intended destination. "FDA clearance for Pivot represents years of focused innovation to deliver a truly differentiated tubeless patch pump. By addressing the key barriers — complexity, bulkiness, and cost — Pivot gives 'almost-pumpers' a reason to finally make the switch. We're excited to begin getting this technology into the hands of patients who have been waiting for something different." That framing — "a reason to finally make the switch" — is not incidental language. It reflects Modular Medical's core commercial thesis: that the market failure in pump adoption was not about clinical need or patient desire, but about product-market fit. The three Cs the company identified were not just engineering targets. They were the barriers that prior device generations failed to adequately address.
Earlier, in August 2025 at the Association of Diabetes Care & Education Specialists conference in Phoenix, Besser had introduced the Pivot's gamified training module developed in collaboration with Level Ex, the creators of Level One, a diabetes management game endorsed by Breakthrough T1D. The move signaled that Modular Medical was thinking about the full patient adoption curve, not just device clearance. Getting a patient to try a pump is only the first step. Keeping them engaged with it is the harder problem, and one the company appears to be approaching with unconventional thinking.
For much of its public history, Modular Medical operated as a development-stage company — a classification that carries a specific kind of market skepticism. Development-stage medical device companies are evaluated on milestones, not revenue, and the finish line always seems to be one regulatory cycle away. That chapter is now closing. With FDA 510(k) clearance secured and PivotPump.com live, Modular Medical has moved the focus of its story from "when will it be cleared" to "how quickly can it scale."
The fall 2026 commercial launch window is now the central timeline event for this company's story. Initial patients were expected to begin using the system as of June 2026. CE Mark certification, targeting the European market, is penciled in for Q4 2026 to Q1 2027. Software roadmap updates, including automated insulin delivery compatibility, are actively in development. The commercialization architecture also appears deliberately lean. Rather than building an internal sales force from scratch, the company's design and pricing approach targets affordability as a market access strategy, potentially reducing the friction of institutional and payer negotiations that often bog down medical device rollouts. PivotPump.com represents the patient-facing front of that strategy — a direct-to-consumer signal that Modular Medical is thinking about the full funnel: from awareness, to education, to adoption. For an under-the-radar medical device company targeting an underserved patient segment, that kind of digital infrastructure early in the commercialization arc is a detail worth noting.
NEWS
8 hours ago
Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump
Jun 4, 2026
Apr 29, 2026
Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock
Apr 19, 2026
Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Apr 16, 2026
Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump
Apr 9, 2026
Modular Medical Announces 1-for-30 Reverse Stock Split
Mar 26, 2026
Modular Medical Announces $12.0 Million Public Offering Priced at a Premium to Market
Mar 3, 2026
Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
Feb 4, 2026
Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule
Dec 31, 2025
MANAGEMENT
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
WE HAVE BEEN COMPENSATED A FEE OF TWENTY TWO THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY MODD AWARENESS CAMPAIGN ON 6/24/26.
WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY MODD AWARENESS CAMPAIGN.WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY MODD AWARENESS CAMPAIGN.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.